About Us
Medriva is part of the ProcureNet family.
The revolution
Innovation, it’s more than a science
Founded by serial entrepreneur Gurbaksh Chahal, Medriva manufactures and distributes two lines of products: In Vitro Diagnostics and Injections & Infusion. The Company utilizes all of ProcureNet’s technology for its rapid scale manufacturing capabilities.
Under its Injections & Infusions division, the Company is on track to manufacturer and distribute over two billion auto-disabled syringes for its clients that include multi-country buying organizations: PAHO, UNICEF, WHO, and the ministries of health for over 20 countries across Asia, Europe & Oceania.
Effectiveness of 98.5%
Medriva COVID-19
Rapid Antigen Self-Test Kits
Medriva COVID-19 Rapid Antigen Self-Test Kits
The Company also manufactures rapid antigen test kits that detect SARS-COV-2 pathogens. The Medriva COVID-19 Rapid Antigen Self-Test Kit is one of the most effective (nasal swab) antigen tests on the market — having a 97.9 percent “sensitivity rate” and a 99.9 percent “relative specificity” rate. Its overall effectiveness is 98.5 percent and is clinically tested to detect both Omicron and Delta variants.
Effectiveness of 98.5%
International Recognition
The IVD division is on track to sell over 300 million rapid test kits and is available in thirty countries that include: Australia, Austria, Belgium, Brunei, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, Honduras, Hong Kong, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malaysia, Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, Thailand and Ukraine.
The company
Globally recognized
Our recent worldwide pandemic work has been documented by organizations such as NY Times. As a direct result, The Company has aided hundreds of millions of citizens across six continents to help fight COVID-19.
Medriva is built on protection
there using innovation, product development, and
the most advanced R&D team.